Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study

Next Previous
Trial Profile

The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evacetrapib (Primary) ; Atorvastatin; Ezetimibe
  • Indications Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCENTUATE
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 01 Feb 2022 Results from ctp:700008441 and ctp:248832 published in the Arteriosclerosis Thrombosis and Vascular Biology
  • 12 Oct 2015 Status changed from recruiting to discontinued following premature cessation of the large cardiovascular outcomes trial (ACCELERATE) evaluating the impact of evacetrapib due to clinical futility, according to results published in the Atherosclerosis Journal.
  • 20 May 2015 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top